Z-VAD-FMK

For research use only. Not for use in humans.

目录号:S7023 别名: Z-VAD(OMe)-FMK

Z-VAD-FMK Chemical Structure

CAS No. 187389-52-2

Z-VAD-FMK (Z-VAD(OMe)-FMK)是一种细胞渗透性的,不可逆泛caspase抑制剂,在THP.1 和 Jurkat T细胞中阻断细胞凋亡的所有特性。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 6953.84 现货
RMB 962.65 现货
RMB 3841.92 现货
RMB 9746.63 现货

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Z-VAD-FMK发表文献687篇:

产品安全说明书

Caspase抑制剂选择性比较

生物活性

产品描述 Z-VAD-FMK (Z-VAD(OMe)-FMK)是一种细胞渗透性的,不可逆泛caspase抑制剂,在THP.1 和 Jurkat T细胞中阻断细胞凋亡的所有特性。
特性 Z-VAD-FMK是研究细胞凋亡的一种关键化合物。
靶点
Pan-caspase [1]
(THP.1, Jurkat T-cells)
体外研究

Z-VAD-FMK (10 μM)作用于THP.1细胞,抑制细胞凋亡。Z-VAD-FMK(10 μM)作用于THP.1细胞裂解液,抑制PARP蛋白酶活性的激活。Z-VAD-FMK (10 μM)作用于完整THP.1和 Jurkat细胞,抑制CPP32加工。[1]Z-VAD-FMK(50 μM)与Camptothecin共处理HL60细胞,废除Camptothecin处理的细胞凋亡形态。Z-VAD-FMK(50 μM)作用于HL60细胞,抑制Camptothecin诱导的DNA分裂。[2]Z-VAD-FMK (50 μM)作用于S2细胞,提高转染细胞的生存百分数从26%提高到63%。[3]Z-VAD-FMK(>100 μM)作用于人类嗜中性粒细胞,增强TNFα-诱导的中性粒细胞凋亡,较低浓度(1-30 μM)时完全抑制TNFα刺激的细胞凋亡。[4]Z-VAD-FMK (10 mM) 作用于早期角膜基质细胞,抑制细胞凋亡。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U937 Mly5RZBweHSxc3nzJGF{e2G7 MnyzOVDPxE1? NF7zZnA1QGh? NF\KdVZz\WS3Y3XzJINmdGxiZHXheIgh[2G3c3XkJIJ6KFONST3JTUB1emWjdH3lcpTDqA>? NGnvTYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiyOFA1Oyd-MkW4NlQxPDN:L3G+
HL-60 MmO1RZBweHSxc3nzJGF{e2G7 MlT6OVDPxE1? NVTFc3V4PDiq MXry[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JHNMUS2LSTD0doVifG2nboVCpC=> NUfaOVFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NlQxPDNpPkK1PFI1ODR|PD;hQi=>
DTK-SME MU\BdI9xfG:|aYOgRZN{[Xl? NFnpW2o2OM7:TR?= NEnyXZozcA>? MmjlSG1UVw>? MUXwZZJ1cWGubImgbY5pcWKrdIOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHL1dIl3[WOjaX7l M4f1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OESzPFk4Lz5{NUi0N|g6PzxxYU6=
HCT116  NVjTXFBISXCxcITvd4l{KEG|c3H5 M{XmRVUx|ryP NF;qTJMzcA>? NEK0XpdqdmirYnn0d{B1cGViY3XscEBl\WG2aDDpcoR2[2WmIHL5JGRFXlB? MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4OEixPEc,OjV6Nki4NVg9N2F-
SGN NIixfoZCeG:ydH;zbZMhSXO|YYm= NH\EdXIzOG2P MojnOFhp MnzrbIF{KG6xIHnu[ox2\W6lZTDvckBCUUZuIHPhcJBicW5iZYjwdoV{e2mxbjDvdkBk\WyuIHHwc5B1d3Orcx?= NGfleGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3OFY{Oyd-MkW4O|Q3OzN:L3G+
A549/V16 M3;WcGFxd3C2b4Ppd{BCe3OjeR?= M1;rNVUx|ryP NYPybHFlOWh? NI[yTZRz\XC{ZYPz[ZMhXEdxVF2tbY5lfWOnZDDhdI9xfG:|aYO= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2NkCzN{c,OjV7NE[wN|M9N2F-
U1 NV21bYZyU2mwYYPlJGF{e2G7 MkGwNVAx|ryP MnjmNog> Mny3bY5pcWKrdIOgZ4F{eGG|ZT2z MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7OEC5OFIoRjJ3OUiwPVQzRC:jPh?=
ACH-2 NYjCOnJqSXCxcITvd4l{KEG|c3H5 NYTnWJdZOC1{MEFOwG0> M1;Q[FJp M2PV[pJm\HWlZYOg[JJ2\y2rbnT1Z4VlKGGyb4D0c5NqeyCjbnSgd5Vje2WzdXXueEBJUVZvMTDy[ZBtcWOjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M2L3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUiwPVQzLz5{NUm4NFk1OjxxYU6=
U1 NV24[m1{SXCxcITvd4l{KEG|c3H5 MWSwMVExOM7:TR?= MW[ybC=> NHvjUldz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NV3ueHlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PFA6PDJpPkK1PVgxQTR{PD;hQi=>
HUVEC-2c NIG0foNCeG:ydH;zbZMhSXO|YYm= MXG1NO69VQ>? MlewOog> M1PtTIRm[3KnYYPl[EB1cGVib4itUGRNNWmwZIXj[YQh[XW2b4DoZYd6 MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{MUeyPUc,OjZyMkG3Nlk9N2F-
SP2/0 NFLEW5dCeG:ydH;zbZMhSXO|YYm= NXPsUFNLOTByzszN NXTSWJhNOWh? NFPSc3BFVVOR M3fncoJtd2OtczD0bIUh[XCxcITvd4l{KG:oIGPQNk8xKGOnbHzz MoG0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyN{S3N|IoRjJ4MEe0O|MzRC:jPh?=
CEF M33lW2tqdmG|ZTDBd5NigQ>? NVruRXZTOCx|Mzy2O{wyODEQvF2= NG\yVW8yPW2rbh?= MWLkc5dvNXKnZ4XsZZRmeyCSUjDlcpp6dWViYXP0bZZqfHlidH:gOFDwxIViYYSgNVAx|ryP M{D2N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUCyN|M6Lz5{NkGwNlM{QTxxYU6=
BEL-7402 NVq2e3M1SXCxcITvd4l{KEG|c3H5 MVGyNO69VQ>? MXmxbC=> NIfQTZpifHSnboXheIVlKHSqZTDhdI9xfG:2aXOgbY5lfWO2aX;uJI9nKEmLST2xNOKh NVPZZXlvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xOlQ4QTVpPkK2NVY1Pzl3PD;hQi=>
HepG2 MVPBdI9xfG:|aYOgRZN{[Xl? MUeyNO69VQ>? M4HGeVFp M3jVOoF1fGWwdXH0[YQhfGinIHHwc5B1d3SrYzDpcoR2[3Srb36gc4YhUUmLLUGwxsA> Mo[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkS3PVUoRjJ4MU[0O|k2RC:jPh?=
HGL5 MoD2RZBweHSxc3nzJGF{e2G7 M4\zNVUx|ryP NITmcIUzPGh? M2K1WIlv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRm Mom0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkmwO|UoRjJ4MU[5NFc2RC:jPh?=
GC1a NWnrTFJTSXCxcITvd4l{KEG|c3H5 MUG1NO69VQ>? MmWwNlRp NYL2T5NFcW6maXPheIV{KGFicILveIVkfGm4ZTDl[oZm[3RiYXfhbY5{fCCndH;wc5Nq\GV? NFfieXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2PVA4PSd-Mk[xOlkxPzV:L3G+
A549 M3jiTmFxd3C2b4Ppd{BCe3OjeR?= MnTKNlAh|ryP MVqyOIg> MVXy[YR2[2W|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JGhHS1BidILlZZRu\W62 M2H3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{m0NVQ6Lz5{NUe5OFE1QTxxYU6=
HeLa M2f0SGFxd3C2b4Ppd{BCe3OjeR?= NEn0PIcyOM7:TR?= M1:4fFQ5cA>? MYLk[YNtcW6nczD0bIUhemG2ZTDv[kBieG:ydH;zbZMh\HKjbXH0bYNidGy7 NHPUT5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3NlU1PSd-MkW3O|I2PDV:L3G+
SGC-7901 NGnpRYdCeG:ydH;zbZMhSXO|YYm= NWKxe2xZOjEEoN88US=> Mn7KNYg> Mn3XbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=> MlvlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkewO|YoRjJ3N{[3NFc3RC:jPh?=
MCF-7 MnnyRZBweHSxc3nzJGF{e2G7 M3z4cFEx|ryP Mmj4Nog> MU\pcohq[mm2czD0bIUh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IEPC MlS3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkKxNVQoRjJ3N{KyNVE1RC:jPh?=
A549 MXLBdI9xfG:|aYOgRZN{[Xl? NGLL[WQyOCEQvF2= MXSyOIg> M3vMd2ROW09? M2Tyd5Bzd22xdHXzJGhDSy22cnXheIVlKEF3NEmgZ4VtdCC|dYL2bZZidCBoIHH0eIVvfWG2ZYOgeIhmKGOuZXH2[YQhWEGUUDDlfJBz\XO|aX;u M1TLNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkizOVY5Lz5{NU[4N|U3QDxxYU6=
U87 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\mOVDPxE1? NWC5RWNuOWh? MX\y[YNwfmW{czDj[YxtKGe{b4f0bEBnem:vIGTNXkB1emWjdH3lcpQ> NIL1UXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NVY3QCd-MkW2PFE3Pjh:L3G+
Neocortical Neuron NVrGPGE2VmW3cn;0c5hq[2m2eTDBd5NigQ>? Mn\KNVAx|ryP M{LXTFFp MYrhcpRi\2:waYrld{BJd2mjbXnk[UBCNUmwZIXj[YQhVmW3cn;0c5hq[2m2eR?= MknmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4N{WwNFEoRjJ3Nke1NFAyRC:jPh?=
Primary human placental cytotrophoblasts M4DDTGFxd3C2b4Ppd{BCe3OjeR?= NWr1R|NyOzEQvF2= MYKyOIg> MlvXSG1UVw>? MlyxdoV3\XK|ZYOgeIhmKGmwaHnibZRqd25ib3[gNVHPui2KU1SyJIJ6KHS{aXPsc5NidsLi MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NEK1PVIoRjJ3NkSyOVkzRC:jPh?=
MM NH3LfllCeG:ydH;zbZMhSXO|YYm= NXHZephbPTEQvF2= MUGyNI1qdg>? Ml;PdIFzfGy7IHnubIljcXS|IGPIT{1qdmS3Y3XkJEBk\WyuIHTlZZRp M4Tpe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUOwNFk5Lz5{NUWzNFA6QDxxYU6=
DLD1 MYPBdI9xfG:|aYOgRZN{[Xl? NF20RW8zOMLizszN NV;GUJZoOWh? NE\LOGhx[XK2bImgdoV3\XK|ZYOgZ4VtdCCjcH;weI9{cXNiY3H1d4VlKGK7IGfTVFE> NFnsWYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2